Alfacell 1985 Press Releases Alfacell 1986 Press Releases Press Release Source: Alfacell Corporation February 15, 1985 ALFACELL CORPORATION 225 Belleville Avenue, Bloomfield, N. J. 07003 (201) 748-8082 or 748-8083 Telex: 833231 FOR: ALFACELL CORPORATION Kuslima Shogen 225 Belleville Avenue Bloomfield, NJ 07003 (201) 748-8082 FROM: ALAN BELL & CO. Alan Bell 276 Fifth Avenue Suite 500 New York, NY 10001 (212) 686-6626 February 15, 1985 FOR IMMEDIATE RELEASE
Alfacell Corporation announced today that the preliminary findings obtained from its clinical study conducted with PANNON (NSTT) prompted the Institutional Review Board and medical specialists supervising the trials to authorize a protocol modification combining assessment of efficacy and safety in the patient population for which it is intended. This modification will assess the efficacy of PANNON in terms of any ameliotory changes that can be defined under the "criteria for response." This revision in the testing program coordinates the two original individual steps into one and has the further advantage of examining ascending dosage schedules rather than the more limited one included earlier. Also, the evaluation criteria necessary for the ultimate submission of data to the U.S. Food and Drug Administration will have been incorporated into this first trial rather than waiting for the step-wise sequential program originally intended. Ms. Shogen , Chief Financial and Operating Officer, emphasized that this modification in the program will not prolong the study beyond the time considered as reasonable in the original plans. However, she cautioned, "the results will not be stastistically appraised until all of the data are available in keeping with good clinical methodology. Until the trial is at the point of completion, neither predictions nor the reporting of specifics can be provided without being prejudicial to the study." Ms. Shogen also announced the receipt of substantial financial support from bank loans granted to the Company on most favorable terms in light of the progress of human trials and expanded biological production. In the last two months alone, Alfacell's biological sales for custcm products exceeded $200, 000. Advanced "scale-up" equipment has been added making it possible to expand production 100 fold with further expansion to come. “We are totally delighted with the Company's progress to date", she added. Press Release Source: Alfacell Corporation May 9, 1985 ALFACELL CORPORATION 225 Belleville Avenue Bloomfield, N. J. 07003 (201) 748-8082 or 748-8083 Telex: 833231 FOR: ALFACELL CORPORATION Kuslima Shogen 225 Belleville Avenue Bloomfield, NJ 07003 (201) 748-8082 FROM: ALAN BELL & CO. Alan Bell 276 Fifth Avenue Suite 500 New York, NY 10001 (212) 686-6626 FOR IMMEDIATE RELEASE
May 9, 1985 -- Alfacell Corporation released today in an interim report on the well-controlled clinical trials ongoing in the Dominican Republic in human cancer patients having the following carcinomas: colon, stomach, rectum, breast, larynx or penile indications. "The study was originally designed to evaluate the safety in humans of the animal-derived biological, "PANNON®", preparatory to filing data with the U.S. Food and Drug Administration. The clinical testing has proved that "PANNON®" destroys malignant tissue without affecting healthy tissue. In this short-term study, there have been no observable side-effects. PANNON® has been developed after years of research and product development with myriad tests conducted in animals and in human tissue cultures. The recent clinical trials in humans disclose that the product PANNON® is more effective in humans than in animals permitting lower daily doses to be injected into the bloodstream on a surface area basis to dissolve the tumors. This study, conducted in Class 3 cancer patients (those that are most critical and in whom surgical procedures, chemotherapy or radiation are no longer advised) is limited to those malignant tumors that are easily accessible for biopsy. Alfacell's investigators confirmed their findings by CAT scans, X-rays, pathology and exhaustive blood analysis. Alfacell hastens to inform the medical and scientific community as well as the public, that "PANNON®" is not as yet approved for marketing anywhere in the world. The Company will be filing all data with the Food and Drug Administration in the near future. As additional information becomes available, interim reports will be released." The above statement on behalf of Alfacell Corporation, is attributed to Ms. Tina Shogen, co-developer of PANNON® and Chief Operating Officer of Alfacell Corporation. Press Release Source: Alfacell Corporation May 14, 1985 ALFACELL CORPORATION 225 Belleville Avenue, Bloomfield, N. J. 07003 (201) 748-8082 or 748-8083 FOR: ALFACELL CORPORATION Kuslima Shogen 225 Belleville Avenue Bloomfield, N.J. 07003 (201) 748-8082 FROM: ALAN BELL & CO. Alan Bell 276 Fifth Avenue Suite 500 New York, NY 10001 (212) 686-6626 FOR IMMEDIATE RELEASE
May 14, 1985 -- Alfacell Corporation responded today to the announcement by the United States Food and Drug Administration (FDA) that administrative action has been taken to prevent further shipments of the Company's unapproved anti-cancer biological agent, PANNON, until the Agency has had the opportunity to review the Company's results from its initial clinical trial of the biological agent in Santo Domingo, Dominican Republic. Roger L. Fidler, Vice presidene and General Counsel stated, "The Company has not planned to make additional shipments, so operationally, the Company's progress will not be directly hindered." With respect to the alleged violation of regulations , Mr. Fidler noted, "The Company has a difference of opinion with the Agency regarding its shipment of what the Company believes was an intermediate product, not a finished product." Miss Shogen, Chief Operting Officer of Aliacell Corporation stated, "The Company has complete documentation of our interaction with the Agency in this matter and we will coneinue to engage in an on-going and cooperative dialogue with the FDA. It. remains our intent to file for an IND and BPL in the near future." Mr. Fidler further noted that the Company will respond formally to the FDA by Wednesday at the latest. Press Release Source: Alfacell Corporation May 24, 1985 ALFACELL CORPORATION 225 Belleville Avenue, Bloomfield, N. J. 07003 (201) 748-8082 or 748-8083 FOR: ALFACELL CORPORATION Kuslima Shogen 225 Belleville Avenue Bloomfield, N.J. 07003 (201) 748-8082 FROM: ALAN BELL & CO. Alan Bell 276 Fifth Avenue Suite 500 New York, NY 10001 (212) 686-6626 FOR IMMEDIATE RELEASE
May 24, 1985 - - Alfacell Corporation reported today that the Company had responded to the Food and Drug Administration (FDA) in a detailed communication on May 14, 1985 denying any circumvention of FDA regulations in shipping its test substance, "Pannon" (anti-tumor agent). It documented the ongoing dialogue of the past year that had been held with the highest level of appropriate authorities at the Agency, relating its objectives and supporting information. Alfacell further stated that in the spirit of co-operation the Company will apply to the FDA under the Section recommended by the Agency for the right to export "Pannon" for the purpose of scientific investigation in the future. "Every effort has been made by the Company to comply with the FDA regulations, and these efforts will continue, as will the Company's policy of complete co-operation with the FDA. At no time in this research stage has Alfacell failed to inform responsible personnel at the FDA Division of Biologics," said Ms. Tina Shogen, Chief Operating Officer of Alfacell. With respect to the ongoing tests in the Dominican Republic, Alfacell also stated it has extended an invitation to the FDA to audit the study underway at the clinical site, and is currently preparing for a pre-filing conference at the Agency. The Company also noted that certain statements have recently appeared in the press, charging that "many insiders have sold large blocks of the Company's stock". The Company believes that such statements are grossly misleading and unfair. To date, the Company's two dominant shareholders, as well as all officers and directors, have not sold one share of stock under SEC Rule 144. The Company is outraged at published statements to the contrary. "We are very concerned over the tendency of some members of the media to persist in carrying statements about us that have little or no basis in reality. We do ask that members of the media understand that we appreciate the importance of the product we have under test and we stand ready at all times to answer questions and whenever possible to be available for comment", Ms. Shogen said. The Company also said it is urging its shareholders to take delivery of stock certificates in order to reduce the problems associated with communicating with them. Press Release Source: Alfacell Corporation July 9, 1985 ALFACELL CORPORATION 225 Belleville Avenue, Bloomfield, N. J. 07003 (201)748-8082 or 748-8083 FROM: ALAN W. BELL CO. (By: Alan Bell) 276 Fifth Avenue New York, NY 10001 (212) 686-6626 FOR: ALFACELL CORPORATION (Ms. Tina Shogen, Vice President) 225 Belleville Avenue Bloomfield, NJ 07003 (201) 748-8082 FOR IMMEDIATE RELEASE
BLOOMFIELD, N. J., July 9, 1985 -- Dr. Stanislaw M. Mikulski, formerly Special Assistant to the Chief of Investigational Drug Branch of the National Cancer Institute, and a Diplomate of the American Board of Medical Oncology, has joined Alfacell Corporation as Medical Director. Dr. Mikulski, a Fellow of the American College of Physicians, now is in private practice, specializing in medical oncology and internal medicine. He also is Clinical Assistant Professor of Medicine at the University of New Jersey Medical School. The announcement of his appointment was made today by Ms. Tina Shogen, Chief Operating Officer of Alfacell, after Dr. Mikulski returned from a fact-finding visit to the clinic in the Dominican Republic where terminal cancer patients are receiving the anti-tumor agent, "PANNON". Pointing out that his on-site appraisal just completed was brief, Dr. Mikulski said, "Investigations being made at the test site show a degree of tissue necrosis in some tumors that is very substantial. Most results over the short term have been especially encouraging, particularly in cancers that are notorious for their resistance to conventional therapy. It should be anticipated however, that not all tumors will respond in the same manner. "Without question, my trip has made me think that this product definitely warrants further investigation, both on a broader range of tumors and over a longer period of time. In my capacity as Medical Director, I intend to pursue those avenues in the applications filed with the Food and Drug Administration, that will make it possible to test this biological in the United States on human subjects." Dr. Mikulski pointed out that he personally visited with the patients currently in the clinical trials, and relies on the extensive pathology reports and the complete case histories for his understanding of the subjects treated and released. He said he had been especially impressed with the spotless conditions at the clinic, and with the excellence of the care. "The patients love it, and get very good attention," he said. Press Release Source: Alfacell Corporation July 12, 1985 Alfacell Corporation 225 Belleville Avenue. Bloomfield, N. J. 07003 (201) 748-8082 or 748-3083 FROM: ALAN W. BELL COMPANY (By Alan Bell) 276 Fifth Avenue New York, N.Y. 10001 (212) 748-8082 FOR: ALFACELL CORPORATION (Ms. Tina Shogen) 225 Belleville Avenue (201) 748-3082 FOR IMMEDIATE RELEASE
BLOOMFIELD, N.J., July 12, 1985 - - Alfacell Corporation and the U.S. Food and Drug Administration today set August 7 as the date of the long awaited pre-filing conference in regard to the beginning of official government evaluation of Alfacell's anti-tumor biological, "Pannon". The product has been used in a clinical trial involving terminally ill cancer patients over the course of the past several months. As has been announced earlier, specialists overseeing the clinical trial conclued "Pannon" is effective against malignant tissue involving several types of cancers, with no significant adverse side effects observed to date. At the pre-filing conference a team from Alfacell will present in minute detail all aspects of all types of testing done to date and will submit to the Food and Drug Administration all case histories. Today's Alfacell announcement follows by only several days its disclosure that a former medical staff member of the National Cancer Institute, Dr. Stanislaw Mikulski, who is a Diplomate of the American Board of Medical Oncology, visited the test site in the Dominican Republic this month as a medical investigator. On his return to the United States, it was announced he is joining Alfacell as its Medical Director. * * * Press Release Source: Alfacell Corporation August 12, 1985 ALFACELL CORPORATION 225 Belleville Avenue, Bloomfield, N. J. 07003 (201) 748-8082 or 748-8083 Telex: 833231 FROM: ALAN W. BELL COMPANY (BY Alan Bell) 276 Fifth Avenue New York, NY 10001 (212) 686-6626 FOR: ALFACELL CORPORATION (Ms. Kuslima {Tina} Shogen, Vice President) 225 Belleville Avenue Bloomfield, NJ 07003 (201) 748-8082 FOR IMMEDIATE RELEASE
Bloomfield, NJ August 12, 1985 -- Alfacell Corporation, developer of the anti-cancer biological, "PANNON", announced today it has met, as scheduled, for a pre-filing conference with the Center for Drugs and Biologics of the United States Food and Drug Administration. As a result, the Company will be filing an IND (Investigational New Drug) application, and be requesting permission to conduct human trials in the United States. Dr. Stanislaw M. Mikulski, Medical Director for Alfacell, a Diplomate of the American College of Medical Oncology, and formerly Special Assistant to the Chief of Investigational Drug Branch of the National Cancer Institute, spoke for Alfacell in saying he was extremely gratified by the response and courtesies received from the FDA staff at the meeting. Dr. Angel S. Chan Aquino, former Minister of Health of the Dominican Republic, and director of the clinical trial that was the basis for the FDA conference, said at the meeting that all of the 27 terminal cancer patients treated showed significant malignant cell destruction. Press Release Source: Alfacell Corporation September 11, 1985 ALFACELL CORPORATION 225 Belleville Avenue, Bloomfield, N. J. 07003 (201) 748-1082 or 748-8083 Telex: 833231 FOR: ALFACELL CORPORATION Tina Shogen 225 Belleville Avenue Bloomfield, NJ 07003 (201) 748-8082 FROM: ALAN BELL & CO. Alan Bell 276 Fifth Avenue New York, NY 10001 (2l2) 686-6626 FOR IMMEDIATE RELEASE
Bloomfield, New Jersey, September 11, 1985 -- Alfacell Corporation today announced that it had provided an update of the current status of PANNON (anti-cancer study) to about two hundred members of the financial community in New York City. For the first time, the Company described the data being derived from the studies, presented photographic characterization of the gross organ effects from selected patients, plus objective information derived from "in vitro" flow cytometry studies being conducted at an Oncology Institute. These results were obtained from the clinical study recently completed in 24 advanced cancer patients treated in the Dominican Republic. A clinical paper will shortly be presented by Dr. Angel S. Chan Aquino, Chief Clinical Investigator, and Dr. Emil Szebenyi, President of Alfacell, at the Pan American Congress in Costa Rica. Dr. Stanislaw Mikulski, Medical Director of Alfacell, reported on findings using the new flow cytometry technology. Objective computerized data indicative of altered DNA and RNA synthesis, and cessation of cell growth and division in two human cancer cell lines, leukemic and colon were described. Initiation of new animal studies in a major southwestern institute were also reported. Joseph Barrows, Ph.G., Regulatory Consultant, described the discussions which took place with the Food and Drug Administration (F. D .A) in a pre-filing conference on August 7, 1985. He also provided an overall assessment of the case histories. As a result Alfacell expects to file an Investigational New Drug Application (IND ) in approximately two months. Miss Tina Shogen, a co-founder of the Company and co-developer of PANNON, emphasized that the results were not being described as a cure, rather they represent a report of status which in several patients resulted in non-recurrence of cancerous lesions six months after cessation of therapy. It was noted that a single patient did not respond, but she remains under PANNON treatment. Dr. Mikulski reported information, and showed numerous color slides, on the step by step sequence in several patients including several penile cancers and gastro rectal colon cancers. The selective action of PANNON on the tumorous tissue without any ill effects on the adjacent normal tissue was emphasized. Dr. Steven Carson, Consultant, revealed the conversion of previously inoperable tumors to an operable status in three patients, thus, facilitating surgical excision. Roger L. Fidler, Vice President and General Counsel of Alfacell, responded to a number of questions regarding patent status of PANNON, and noted that no assurance can be given that a patent will be granted, or if granted, that such patent could be enforced. In discussion of projected plans, both Miss Shogen and Mr. Barrows indicated that the future clinical program after IND submission includes a multi-center study in the United States. Discussions have also been initiated with an internationally known Oncology Institute with respect to continued animal and human studies. Although the Alfacell support of the PANNON clinical studies in the Dominican Republic have run their course, the remaining clinical supply of PANNON in that country has been made available to the investigators without charge to enable continuing treatment of patients on a private basis. The data derived from these studies will be made available to Alfacell. Mr. Fidler emphasized that PANNON is not now being marketed or sold anywhere nor has it been approved by the United States Regulatory Authorities nor can any assurance be given that any such approvals will be granted in the future. Press Release Source: Alfacell Corporation November 21, 1985 ALFACELL CORPORATION 225 Belleville Avenue, Bloomfield, N. J. 07003 (201) 748-8082 or 748.8083 Telex: 833231 FROM: ALAN W. BELL COMPANY (Alan Bell) 276 Fifth Avenue New York, NY 10001 (212) 686-6626 FOR: ALFACELL CORPORATION (Ms. Tina Shogen, Chief Operating Officer) 225 Belleville Avenue Bloomfield, NJ 07003 (201) 748-8082 FOR IMMEDIATE RELEASE
Bloomfield, NJ, November 21, 1985 --- Alfacell corporation, producers of the anti-cancer biological, "PANNON®", filed with the United States Food and Drug Administration today the Investigational New Drug Application for PANNON®. This will permit early human trials in the United States on cancer subjects. These trials will be conducted in a number of prestigious institutions in the United States and abroad. Alfacell also announced that the first report to the medical community on clinical studies regarding PANNON® will be presented at the Sixth Annual Congress on Oncology for Central America, Panama and the Caribbean, sponsored by the Costa Rican Association of Oncology, to be held December 1 to 6, 1985, at San Jose, Costa Rica. The presentation will be made by the doctors who conducted the initial human trial in Santo Domingo, Dominican Republic. Leading the presentation will be Dr. Mario Ravelo, M.D., Ph.D., Diplomate of the American College of Pathology, who served as pathologist for the clinical trial. Accompanying Dr. Ravelo will be Angel S. Chan, M.D., former Minister of Health of the Dominican Republic, Chief Investigator of the clinical trial, and Stanislaw Mikulski, M. D., Diplomate of the American Board of Medical Oncology, former medical staff member of the National Cancer Institute, who is Medical Director of Alfacell. Accompanying the investigators to the Conference, and participating in the formal discussion, will be Emil Szebenyi, Ph.D., President of Alfacell, and Ms. Tina Shogen, Chief Operating Officer. Dr. Szebenyi served as an on-site monitor of the clinical trial. Dr. Szebenyi and Ms. Shogen are the co-developers of PANNON and founders of Alfacell Corporation. Press Release Source: Alfacell Corporation June 17, 1986 ALFACELL CORPORATION 225 Belleville Avenue, Bloomfield, N. J. 07003 (201) 748-8082 or 748-8083 Telex: 833231 FROM: ALFACELL CORPORATION (Ms. Kuslima Shogen, Chief Operating Officer) 225 Belleville Avenue Bloomfield, NJ 07003 (201) 748-8082 BY: ALAN W. BELL CO. , INC. (Alan Bell) 276 Fifth Avenue New York, NY 10001 (212) 680-6026 FOR IMMEDIATE RELEASE
June 17, 1986 -- Alfacell Corporation announced today that it is preparing to file the amendment containing additional data with the Food and Drug Administration ("FDA") concerning its anti-cancer biological, PANNON. These efforts, which concentrate on identifying the chemical constituents and characterization data, also include the identification and characterization of "active" fractions isolated from the PANNON formulation. Parallel studies include the development of an "intact" animal assay with animal and human tumors for the correlation with the tissue culture data. This additional study could materially enhance the commercialization of this product and its market potential. The Company, which originally intended to file its additional data with the FDA in June, decided after its last discussion with the FDA, to expand its submission before filing the Amendment. As soon as we have filed, we will report to our shareholders. The Company currently has one class of warrants outstanding, known as its Two-Year Warrants (carrying a "B" number). Each warrant is transferrable for one share of Alfacell Common Stock. The Warrants are due to expire July 17, 1986, at the exercise price of $10.00 per share. Payment must be received by Alfacell by that expiration date, without fail, inasmuch as the Two-Year Warrants will not be extended. The following is an outline concerning the details of the exercise of your warrants: 1. If the Warrant Certificate is held in your own name: Fill out the instructions on the back of the Warrant Certificate. If you want the stock issued to a different name than shown, enclose such instruction. Send the signed Warrant Certificate, your instructions and your check payable to Alfacell, either to your broker with instructions that it be forwarded to Alfacell or write directly to Alfacell. In either case, we recommend you use Certified Mail, Return Receipt Requested. 2. If the Warrant is held in street name by your broker: Write appropriate instructions to your broker letting him know that you want to exercise your Warrants, and enclose your check in the proper amount. We again recommend you use Certified Mail, Return Receipt Requested. In all cases Alfacell will forward instructions to the transfer agent who will issue common stock certificates to you or to your broker, however requested in the Warrant Certificate. If you have any questions regarding the exercise of the Warrants, please telephone Ina Siegel at Alfacell (201) 748-8082. Press Release Source: Alfacell Corporation July 1, 1986 ALFACELL CORPORATION 225 Belleville Avenue, Bloomfield. N.J. 07003 (201) 748-3082 or 748-3083 FROM: ALFACELL CORPORATION (Ms. Kuslima Shogen, Chief Operating Officer) 225 Belleville Avenue Bloomfield. NJ 07003 (201) 748-8082 BY: ALAN W. BELL CO., INC. (Alan W. Bell) 276 Fifth Avenue Suite 500 New York, NY 10001 (212) 686-6626 FOR IMMEDIATE RELEASE
Bloomfield, New Jersey, July 1, 1986, -- Alfacell Corporation, in an updating on its anti-cancer biological, "PANNON", announced today it has selected five major hospitals in which to hold clinical trials for efficacy and has signed agreements with prestigious investigators at these institutions. Three of the hospitals are in the United States and two are well recognized foreign institutions. The trials are to start in the Fall of this year, when Alfacell has on hand enough of its new purified "PANNON" to satisfy clinical trial requirements for a substantial number of patients. The trials will commence after Alfacell files its amended Investigational New Drug Application this Summer with the United States Food and Drug Administration. This amendment covers the detailed analysis and further purification of "PANNON" and its fractions. The entire process now is undergoing final chemical content confirmation and studies of anti-tumor activities in animals bearing human tumors. Confirmatory animal studies are a routine procedure in any drug development in the pharmaceutical industry. The Company also announced it is filing worldwide patent applications in the important marketing and manufacturing countries. Alfacell is committed to getting the fullest support for its technology. Ms. Tina Shogen, Chief Operating Officer of Alfacell, said: “This updating today vindicates the confidence Alfacell has in its scientists and consultants. who are succeeding in the detailed analysis of “PANNON”. This progress indicates that it now is time to secure worldwide patents to protect our unique product. “It has not been easy for this Company to have paused deliberately as we have done for the past several months in starting large-scale efficacy trials in humans. But the time and funds invested have proven to be totally justified, and, indeed, in the best interests of our shareholders. Press Release Source: Alfacell Corporation July 15, 1986 ALFACELL CORPORATION 225 Belleville Avenue, Bloomfield. N.J. 07003 (201) 748-3082 or 748-3083 Telex: 833231 FROM: ALFACELL CORPORATION (Ms. Kuslima Shogen, Chief Operating Officer) 225 Belleville Avenue Bloomfield. NJ 07003 (201) 748-8082 BY: ALAN W. BELL CO., INC. (Alan W. Bell) 276 Fifth Avenue Suite 500 New York, NY 10001 (212) 686-6626 FOR IMMEDIATE RELEASE
Bloomfield, New Jersey, July 15, 1986 -- Alfacell Corporation, makers of the anti-cancer biological, PANNON, announced today it has extended for one month to August 18 the Company's $10.00 1986 warrants that have been due for conversion by July 17. Ms . Tina Shogen, Chief Financial and Operating Officer,said: "Extending the warrants is designed to be fair to the long-term investors who have financed our years of research and gives them the opportunity to share in our expected good fortune in the future. Ms. Shogen noted some warrants already have been converted in recent days, on the basis of one warrant for one share of common stock at $10.00. "The Company believes conversion is justified based on Alfacell’s scientific results and prospects,” she said. Press Release Source: Alfacell Corporation August 13, 1986 ALFACELL CORPORATION 225 Belleville Avenue, Bloomfield. N.J. 07003 (201) 748-3082 or 748-3083 Telex: 833231 FROM: ALFACELL CORPORATION (Ms. Kuslima Shogen, Chief Operating Officer) 225 Belleville Avenue Bloomfield. NJ 07003 (201) 748-8082 BY: ALAN W. BELL CO., INC. (Alan W. Bell) 276 Fifth Avenue Suite 500 New York, NY 10001 (212) 686-6626 FOR IMMEDIATE RELEASE
Bloomfield, New Jersey, August 13, 1986 ---- Alfacell Corporation, makers of the anti-cancer biological, PANNON, announced today it has filed for an extension of the 1986 class B warrants. The new expiration date is October 31, 1986. Press Release Source: Alfacell Corporation October 29, 1986 ALFACELL CORPORATION 225 Belleville Avenue, Bloomfield. N.J. 07003 (201) 748-3082 or 748-3083 Telex: 833231 FROM: ALFACELL CORPORATION (Ms. Kuslima Shogen, Chief Executive Officer) 225 Belleville Avenue Bloomfield. NJ 07003 (201) 748-8082 BY: ALAN W. BELL CO., INC. (Alan Bell) 276 Fifth Avenue Suite 500 New York, NY 10001 (212) 686-6626 FOR IMMEDIATE RELEASE
Bloomfield, NJ, October 29, 1986 -- Alfacell Corporation today announced that it has submitted the amended information to the Food and Drug Administration ("FDA"). This submission embodies the extensive research efforts that have been underway for the past several months on "PANNON". Alfacell Corporation further announced that Ms. Kuslima Shogen, Chief Financial and Operating Officer has been elected President and Chief Executive Officer. Dr Stanislaw M. Mikulski, who previously held the post of Medical Director of Alfacell, has been elected Executive Vice President, Medical Director and Director of Laboratories. Dr. Mikulski formerly was Special Assistant to the Chief, Investigational Drug Branch, National Cancer Institute, and Coordinator for Immunotherapy Trials in Cancer for the Division of Cancer Treatment, NCI, following his post-doctoral studies at UCLA in Human Tumor Immunology. He is a Diplomate of the American Board of Internal Medicine and Medical Oncology, as well as a Fellow of the American College of Physicians. Dr. Mikulski is Clinical Assistant Professor of Medicine, at the University of Medicine of New Jersey Medical School. In commenting on the election of Dr. Mikulski, Ms. Shogen said: "Alfacell is fortunate to have Dr. Mikulski join us as Executive Vice President. He brings his expertise not only from the medical point of view, but is extremely astute in research methodology that has earned him enormous respect among his peers." Ms. Shogen and Dr. Mikulski announced the following new members to the Scientific Advisory Board who will be working with the Company on its scientific and clinical testing programs: Eugene H. Bernstein, Ph.D., is Visiting Professor, Waksman Institute of Microbiology, Rutgers University, Virology Department; and is presently conducting studies in toxicology and chemotherapy at Robert Wood Johnson Medical School, Rutgers University. Dr. Bernstein conducted the National Institute of Health (NIH) Cancer Chemotherapy Screening Program on Rous Sarcoma and also has served as principal investigator and director of a number of National Cancer Institute (NCI) programs in the area of virology. Michael A. Chirigos, Ph.D., is Deputy for Science, U.S. Army Medical Research Institute of Infectious Diseases. Dr. Chirigos formerly was with the National Cancer Institute (NCI), Division of Cancer Treatment, Biological Response Modifiers Program. Zbiginew Darzynkiewicz, M.D. Ph.D., is an Associate Member nf Sloan-Kettering Cancer Research Center; Associate Professor of CorneJl University Graduate School of Medical Sciences and President-elect of the International Cell Kinetics Society. Harry Salem, Ph.D., is Chief of the Toxicology Division, U.S. Army Chemical Research and Development Center. Dr. Salem is certified as a Diplomate in General Toxicology by the Academy of Toxicological Sciences. He serves on a number of EditoriaJ Boards and is North American editor of the Journal of Applied Toxicology. ###
Press Release Source: Alfacell Corporation December 15, 1986 ALFACELL CORPORATION 225 Belleville Avenue, Bloomfield. N.J. 07003 (201) 748-3082 or 748-3083 Telex: 833231 FROM: ALFACELL CORPORATION (Ms. Kuslima Shogen, Chief Executive Officer) 225 Belleville Avenue Bloomfield. NJ 07003 (201) 748-8082 BY: ALAN W. BELL CO., INC. (Alan Bell) 276 Fifth Avenue Suite 500 New York, NY 10001 (212) 686-6626 FOR IMMEDIATE RELEASE
Bloomfield, New Jersey, December 15, 1986 -- Alfacell Corporation, makers of the anti-cancer agent, “PANNON” announced today it has applied to the Securities and Exchange Commission for an extension to July 31, 1987, of Alfacell's outstanding $10.00 Warrants that have been exercisable by December 15, 1986. The Company said the extended warrants will be callable at any time on 15 days notice up to the July 31 expiration date. The Company further reserves the right to issue additional shares of stock as an adjustment to reflect any price differential that may exist. Holders who exercise these warrants will at no time receive less than one share of common stock for each warrant exercised. |